Journals / Dicle Tıp Dergisi / 2020 / Cilt: 47 - Sayı: 2

Investigation of the Relationship Between Serum Solubl Fas (sFas), Soluble Fas Ligand (sFasL) Levels and FAS-FASLG Polymorphisms in Patients with Multiple Sclerosis

Multipl Sklerozisli Hastalarda Serum sFas, sFas Ligand Düzeyleri ile FAS ve FASLG Polimorfizmleri Arasındaki İlişkinin Araştırılması

Pages
331–339
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Our results suggest that FAS -670 AG genotype may play a protective role by reducing the risk (OR=0.475, p=0.014), while the GG genotype is a strong risk factor associated with MS (OR=7.644, p=0.0001), and elevated levels of serum sFasL may contribute to the pathogenesis of the disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Multiple Sclerosis (MS) is an autoimmune disease caused by the reaction of autoreactive T lymphocytes to myelin antigens.
📊
Key Findings & Data:In this study, we aimed to investigate the effect of FAS -670 A/G and FASLG -844 T/C functional gene polymorphisms and serum sFas and sFasL levels on MS development and their contribution to the pathogenesis of the disease.
💡
Conclusion & Impact:Conclusion: Our results suggest that FAS -670 AG genotype may play a protective role by reducing the risk (OR=0.475, p=0.014), while the GG genotype is a strong risk factor associated with MS (OR=7.644, p=0.0001), and elevated levels of serum sFasL may contribute to the pathogenesis of the disease.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Multiple Sclerosis (MS) is an autoimmune disease caused by the reaction of autoreactive T lymphocytes to myelin antigens. Fas-FasL patway plays an important role in T cell apoptosis and It is well known that there are defects in the Fas-FasL pathway in autoimmune diseases. In this study, we aimed to investigate the effect of FAS -670 A/G and FASLG -844 T/C functional gene polymorphisms and serum sFas and sFasL levels on MS development and their contribution to the pathogenesis of the disease. Methods: 108 MS patients and 98 healthy individuals as control group were included in the study. PCR-RFLP technique was used to determine FAS -670 A/G and FASLG -844 T/C polymorphisms. Serum sFas and sFasL levels was measured using the solid phase sandwich ELISA kit. Results: FAS -670 AG genotype frequency in MS patients was lower than healthy controls (p=0.014), while GG genotype frequency was significantly higher in the patient group than healthy controls (p=0.0001). Serum sFasL levels were significantly higher in MS group compared to healthy controls (p=0.015), but sFas levels were similar between the groups (p = 0.705). There was no significant correlation between FAS - FASLG polymorphisms and sFas - sFasL levels. Conclusion: Our results suggest that FAS -670 AG genotype may play a protective role by reducing the risk (OR=0.475, p=0.014), while the GG genotype is a strong risk factor associated with MS (OR=7.644, p=0.0001), and elevated levels of serum sFasL may contribute to the pathogenesis of the disease.

Özet

Amaç: Multiple Sklerozis (MS) otoreaktif T lenfositlerin miyelin antijenlerine karşı gösterdiği reaksiyon sonucu ortaya çıkan otoimmün bir hastalıktır. Fas-FasL yolağı T hücre apoptozisinde önemli bir rol oynamaktadır ve otoimmun hastalıklarda Fas-FasL yolağında defektler olduğu bilinmektedir. Bu çalışmada FAS -670 A/G ve FASLG -844 T/C fonksiyonel gen polimorfizmleri ile serum sFas ve sFasL düzeylerinin MS gelişimine ve hastalığın patogenezine katkısının araştırılması amaçlanmıştır. Yöntemler: Çalışmaya 108 MS hastası ve kontrol grubu olarak da 98 sağlıklı birey dahil edilmiştir. FAS -670 A/G ve FASLG -844 T/C polimorfizmlerinin belirlenmesi için PCR-RFLP tekniği kullanılmıştır. sFas ve sFasL düzeyleri solid fazlı sandviç ELISA kiti kullanılarak ölçülmüştür. Bulgular: MS hastalarında FAS -670 AG genotipi frekansı (%55,55) sağlıklı kontrollere (%72,44) göre düşük (p=0.014), GG genotipi frekansı ise hasta grubunda (%19,44) sağlıklı kontrollere (%3,06) göre anlamlı derecede yüksek bulundu (p = 0.0001). Hasta ve kontrol grupları arasında FASLG -844 T/C polimorfizmi açısından anlamlı bir fark bulunamadı (p > 0.05). Serum sFasL düzeyleri MS grubunda, sağlıklı kontrol grubuna göre istatistiksel olarak anlamlı bir şekilde yüksek bulunmakla (p = 0.015) birlikte, sFas düzeyleri gruplar arasında benzer bulundu (p = 0.705). FAS - FASLG polimorfizmleri ile serum sFas - sFasL düzeyleri arasında anlamlı bir ilişki bulunamadı. Sonuç: Sonuçlarımız FAS -670 AG genotipinin MS riskini azaltarak (RR = 0.475, p = 0.014) koruyucu bir rol oynayabileceğini, GG genotipinin ise MS ile ilişkili güçlü bir risk faktörü (RR = 7.644, p = 0.0001) olabileceğini, serum sFasL düzeylerindeki artışın ise bu faktörün MS patogenezine katkı sunabileceğini gösterebilir.

🔖

Cite This Article

DURAN, G. G., MELEK, İ. M., DUMAN, T., GÜNEŞAÇAR, R. (2020). Investigation of the Relationship Between Serum Solubl Fas (sFas), Soluble Fas Ligand (sFasL) Levels and FAS-FASLG Polymorphisms in Patients with Multiple Sclerosis. Dicle Tıp Dergisi, Cilt: 47 - Sayı: 2, 331–339. https://ajindex.com/articles/159504

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Volpe E, Sambucci M, Battistini L, Borsellino G. Fas–Fas Ligand: Checkpoint of T Cell Functions in Multiple Sclerosis. Front Immunol. 2016; 7: 382
  2. Mohammadzadeh A, Pourfathollah AA, Sahraian MA, et al. Evaluation of apoptosisrelated genes: Fas (CD94), FasL (CD178) and TRAIL polymorphisms in Iranian multiple sclerosis patients. J Neurol Sci. 2012; 312: 166- 9
  3. Xia B, Yu HY, Guo QS, et al. Association of Fas670 gene polymorphism with inflammatory bowel disease in Chinese patients. World J Gastroenterol. 2005; 11: 415-17
  4. Kim KM, Lee K, Hong YS, Park HY. Fasmediated apoptosis and expression of related genes in human malignant hematopoietic cells. Exp Mol Med. 2000; 32: 246-54
  5. Kischkel FC, Hellbardt S, Behrmann I, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)- associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 1995; 14: 5579–88
  6. Gilhar A, Yaniv R, Assy B, et al. Fas pulls the trigger on psoriasis. Am J Pathol. 2006; 168: 170-5
  7. Jalali SA, Shandiz HF, Afshari JT, et al. Status of FAS and FAS Ligand Gene Polymorphisms in Patient with Breast Cancer in Northeastern IRAN. Rep Biochem Mol Biol. 2018; 7: 23-29
  8. Elmore S. Apoptosis: A Review of Programmed Cell Death. Toxicol Pathol. 2007; 35: 495–516
  9. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-56
  10. Meynier S, Rieux-Laucat F. FAS and RAS related Apoptosis defects: From outoimmunity to leukemia. Immunol Rev, 2019; 287: 50-61 11. Rieux-Laucat F, Magerus-Chatinet A, Neven B. The Autoimmune Lymphoproliferative Syndrome with Defective FAS or FAS-Ligand Functions. J Clin Immunol. 2018; 38: 558-68
  11. Kantarcı OH, Hebrink DD, Achenback SJ, et al. CD95 polymorphisms are associated with susceptibility to MS in women. A populationbased study of CD95 and CD95L in MS. J Neuroimmunol. 2004; 146: 162-70
  12. Huang QR, Danis V, Lassere M, Edmonds J, Manolios N. Evaluation of a new Apo-1/Fas promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus patients. Rheumatology. 1999; 38: 645-51
  13. Fisher GH, Rosenberg FJ, Straus SE, et al. Dominant interfering fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 1995; 81: 935-46
  14. Takahashi T, Tanaka M, Inazawa J, et al. Human Fas ligand: gene structure, chromosomal location and species specificity. Int Immunol. 1994; 6: 1567-74
  15. Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the